Pyxis Oncology (PYXS) Return on Sales (2024 - 2025)

Pyxis Oncology (PYXS) reported Return on Sales of 0.02% for Q4 2025, up 3.0% year-over-year from 0.02% in Q4 2024, and up 95.24% quarter-over-quarter from 0.35% in Q3 2025.

Pyxis Oncology (PYXS) Return on Sales (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Return on Sales data on file, last reported at 0.02% in Q4 2025.

  • Return on Sales for Q4 2025 came in at 0.02%, up 3.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.06% (down 1.0% YoY), and the FY2025 annual result was 0.06%, down 1.0% from the prior year.
  • Return on Sales grew to 0.02% in Q4 2025 per PYXS's latest filing, from 0.35% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.0% in Q1 2024 and troughed at 0.35% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.00%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 0.00%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 0.00%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Pyxis Oncology 125.84 Mn 108.95 Mn 8.65 Mn -0.02%

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.02%
Sep 30, 2025 -0.35%
Jun 30, 2025 -0.06%
Dec 31, 2024 -0.05%
Mar 31, 2024 0.00%